Avidity Biosciences is a biopharmaceutical company developing a new class of RNA therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to combine the specificity of monoclonal antibodies, or mAbs, with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. Co.'s lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare monogenic muscle disease. Co. pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy, and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy. We show 15 historical shares outstanding datapoints in our coverage of RNA's shares outstanding history.
Understanding the changing numbers of RNA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like RNA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching RNA by allowing them to research RNA shares outstanding history
as well as any other stock in our coverage universe. |
Free RNA Email Alerts:
Video: Shares Outstanding Importance
